Vaxon Biotech
This article was originally published in Start Up
Executive Summary
Vaxon Biotech is developing therapeutic vaccines that stimulate the immune system to attack cancer cells without harming normal tissue, for a range of indications including prostate, lung, breast, hepatocellular, pancreatic and colon cancer. Based near Paris, Vaxon says it is the first company to develop therapeutic vaccines to treat existing cancers using optimized cryptic peptides, which appear to escape tolerance mechanisms, suggesting their potential in cancer immunotherapy.
You may also be interested in...
Start-Up Previews (6/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: A New Perspective on Cancer Immunotherapy, features profiles of Apthera, Juvaris BioTherapeutics, Pique Therapeutics and Vaxon. Plus these Start-Ups Across Health Care: Acceleron Pharma, CTG Pharma, ImVisioN, and Innovent Medical.
A New Perspective on Cancer Immunotherapy
Many believe that for therapeutic cancer vaccines, a more flexible two-stage system of proof-of-principle trials followed by efficacy trials should replace the current Phase I-III structure. That's because the paradigm used for oncology drug development is based on criteria developed for cytotoxic agents, which present a very different toxicity profile, metabolism, and manner of biological and clinical response.
Start-Up Previews (6/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: A New Perspective on Cancer Immunotherapy, features profiles of Apthera, Juvaris BioTherapeutics, Pique Therapeutics and Vaxon. Plus these Start-Ups Across Health Care: Acceleron Pharma, CTG Pharma, ImVisioN, and Innovent Medical.